Nitrolingual contains nitroglycerin, a long-established molecule classified within a group of vasodilator, antianginal, and cardiac-therapy agents, and the brand is registered in 27 countries. The page you are reading is for international readers — travellers, expatriates, and family members — trying to understand what Nitrolingual is and how it relates to the nitroglycerin products they may already know from another country.
Nitroglycerin is used in the management of angina pectoris and in its prophylaxis, and appears in the registered indications for conditions including coronary heart disease, heart failure, and pulmonary hypertension. The structured indication list further down this page details the specific registered uses of Nitrolingual as recognised by national regulators in the markets where it is sold, alongside the pharmacological categories the active ingredient belongs to.
The countries where Nitrolingual is marketed cluster across Western and Central Europe and extend into the Middle East, North America, and parts of East Asia — examples include Germany, Canada, China, Egypt, and Hungary. Even within this footprint, nitroglycerin circulates in several different formulations intended for different clinical situations, and the specific products available locally vary considerably from one regulatory regime to another. A pharmacist in the destination country is generally the right person to confirm what is on the shelf and under which brand.
Other nitroglycerin-containing products are sold worldwide under a range of brand names, and the broader vasodilator and antianginal category is well represented internationally under other molecules as well. Anyone using Nitrolingual, considering it, or trying to identify a local equivalent while abroad should work with a healthcare provider on that decision rather than making the substitution at the counter.
Nitrolingual is prescribed in the management of angina pectoris, including its prophylaxis, and is also indicated in contexts such as coronary heart disease, heart failure, and pulmonary hypertension. Its active ingredient belongs to a vasodilator and antianginal category of cardiac therapy. The structured indication block further down this page lists each registered use as recognised by national regulators in the markets where Nitrolingual is sold.
Nitrolingual contains nitroglycerin, classified within a group of vasodilator and antianginal cardiac therapies. Nitroglycerin is one of the longest-established molecules in cardiovascular medicine and circulates internationally under a number of different brand names and formulations. The same active ingredient is therefore widely available worldwide, even where the Nitrolingual brand specifically is not on the local market.
Nitrolingual carries marketing authorisation in 27 countries, with a footprint that spans Western and Central Europe, parts of the Middle East, North America, and East Asia. Representative markets include Canada, Germany, China, Egypt, Israel, Hungary, and Belgium. If your country is not on this list, a local pharmacist can usually confirm whether a nitroglycerin-containing product is available under a different brand name in that market.
Nitroglycerin is sold under multiple brand names worldwide and across several different formulations intended for different clinical situations. Other molecules in the broader vasodilator and antianginal category also exist, although they are not freely interchangeable — products within this therapeutic area differ in onset, duration, and clinical positioning. To identify a local nitroglycerin product, search the active ingredient on Pill2Trip or ask a pharmacist in your country.
Yes. Nitroglycerin-containing products are prescription medications in most jurisdictions, and antianginal therapy is calibrated to a patient's full cardiovascular history and concurrent treatments. Prescription rules, available formulations, and brand names vary meaningfully between countries, which matters particularly for travellers and people relocating internationally. Any decision to start, continue, switch, or substitute a nitroglycerin product should involve a healthcare provider familiar with the patient.
